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A combination of favipiravir and zanamivir successfully cleared 
influenza B infection in a child who had undergone bone 
marrow transplant for X-linked severe combined immunode-
ficiency, with no recovery of T lymphocytes. Deep sequencing 
of viral samples illuminated the within-host dynamics of infec-
tion, demonstrating the effectiveness of favipiravir in this case.
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Despite the availability of neuraminidase inhibitors, influenza 
infections in immunocompromised individuals with poor T-cell 
functions continue to have a mortality rate in excess of 20% [1]. 
Favipiravir, a guanosine analogue, has been reported to have in 
vitro activity against influenza [2] and other RNA viruses [3, 4]. 
Results from 2 international, randomized, placebo-controlled, 
Phase III clinical trials, although they suggest accelerated clear-
ance of influenza virus by 6 to 14 hours in healthy, favipiravir-
treated individuals, are unpublished, and the drug remains 
unlicensed in the United Kingdom and United States. Favipiravir 
has been used as a single agent for the treatment of severe in-
fluenza in hospitalized patients, and also against Ebola and 
norovirus, although its efficacy remains uncertain [3–5]. In par-
ticular, the drug levels measured during severe cases of Ebola 
and influenza have been lower than expected, raising questions 
about its bioavailability [5, 6]. Combination therapy with other 
antiviral agents has not been reported, although in vitro synergy 
with neuraminidase inhibitors has been observed [7].
In vitro studies demonstrate that favipiravir inhibits the 
function of RNA-dependent viral polymerases. Sequencing 
of viruses recovered from in vitro experiments suggests that 
favipiravir induces increased mutagenesis, with the resulting 
accumulation of deleterious mutations potentially forcing the 
population to extinction [8]. Single-point mutations in the viral 
polymerase that confer resistance against favipiravir have been 
reported for influenza A that was cultured in vitro [9]. We here 
report the use of favipiravir in combination with neuraminidase 
inhibitors in a profoundly immunocompromised child with in-
fluenza B. Deep sequencing, together with evolutionary model-
ling of viral genomes, provided support for the conclusion that 
this combination was effective and should be considered for the 
treatment of severe influenza infections.
CASE REPORT
The patient developed chronic influenza B at 23  months, fol-
lowing a failed mismatched unrelated donor cord haemopoietic 
bone marrow transplant. Treatment with oseltamivir, zanamivir, 
and nitazoxanide failed to clear the influenza B virus, despite the 
virus testing negative for neuraminidase resistance (Figure 1A). 
Following a second mismatched unrelated donor transplant at 
age 29 months, favipiravir, at an initial dose of 60 mg/kg/day for 
1 day, followed by 23 mg/kg/day 3 times daily for 16 days, was 
added to ongoing zanamivir and nitazoxanide treatment, re-
sulting in the apparent clearance of the virus within 2 weeks de-
spite no evidence of CD4+/CD8+ T-cell recovery. The dose was 
calculated based on the data from favipiravir treatment of Ebola 
virus in children [10]. With the exception of an isolated, posi-
tive sample, the patient tested negative for influenza infection 
until 2 months after stopping treatment, when influenza B was 
again detected. A further 2 weeks of combined favipiravir and 
zanamivir treatment led to the rapid and final clearance of the 
infection. One month after the end of treatment, the patient died 
from ongoing disseminated bacillus Calmette Guérin infection 
and bone marrow failure. He remained negative for influenza.
The viral load declined slowly during the first period of in-
fection, with an approximate 8-fold reduction occurring during 
this period (Figure  1B). No statistical evidence was found 
to associate this decline with the use of either zanamivir or 
nitazoxanide (Supplemental Figure 1), suggesting that these 
drugs were ineffective.
Deep sequencing was performed on 41 influenza-positive 
samples from the patient, giving a detailed insight into the ev-
olution of the viral population. A phylogenetic analysis of con-
sensus haemagglutinin sequences suggested that the recurrence 
of infection arose through recovery of the original viral popu-
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Figure 1. A, As shown at the top, despite the use of multiple antiviral therapies, viral clearance was not achieved until favipiravir combination therapy coincided with 
a fall in viral load to undetectable levels. Approximately 2  months later, after the collection of an isolated, positive sample, a resurgence of infection was observed. 
Combined zanamivir and favipiravir treatment led to the final clearance of the infection. A blue arrow shows the date of a phenotypic test for neuraminidase inhibitor 
resistance, which proved negative. A vertical, blue, dotted line shows the date of the second bone marrow transplant. As shown in the second row, immune cell data 
showed undetectable B cell, CD4+, and CD8+ counts, with natural killer (NK) and γδCD3+ cells increased posttransplantation. Dashed lines show the bottom end of 
normal clinical ranges. In the third row are the median read depths of viral sequencing. In the fourth row are the sequence data, showing the partial, then complete 
prevalence of zanamivir resistance via substitutions to glycine and alanine at locus 117 in neuraminidase. Vertical, dotted lines separate times during which the viral 
population was susceptible, partially, then fully resistant to zanamivir. As shown at the bottom, the use of favipiravir, indicated by purple bars, coincided with an in-
crease in the proportion of cytidine to uridine (C-to-U) variants among low-frequency mutations in the viral population. Vertical bars show intervals of 2 standard devi-
ations for each value, calculated using a bootstrapping procedure. B, Haemagglutinin sequences from the patient form a distinct phylogenetic cluster to the most similar 
sequences found in a global sequence database. No clear evidence was found supporting a separation of samples collected before and after the reversion of infection. 
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formed a clade distinct from the most similar viruses in a global 
database of influenza B sequences (Figure  1B; Supplemental 
Table S1). The lack of a strict time ordering of samples in the tree 
supports the case for a consistent infection; samples collected 
before and after the resurgence were not evolutionarily distinct.
Sequence data showed the partial onset of zanamivir resist-
ance during the first period of infection, before favipiravir was 
introduced. Zanamivir-resistant alleles emerged 17  days after 
the first use of the drug, with valine, alanine, and glycine re-
placing glutamic acid at position 117 in the neuraminidase 
protein; the latter 2 substitutions have known associations with 
drug resistance, with >500-fold loss of sensitivity in the pres-
ence of zanamivir [11]. The population then entered a period 
of partial resistance, with a mix of susceptible and resistant vir-
uses being observed until favipiravir was introduced. Following 
the use of favipiravir, the viral load rapidly fell to undetectable 
levels.
We propose that favipiravir was the inherent cause of the rapid fall 
in the viral load. Consistent with previous in vitro studies, the use of 
favipiravir was associated with an increase in low-frequency cytidine 
to uridine (C-to-U) mutations (Figure 1A) during both periods of 
treatment. No equivalent effects were observed in other mutational 
types (Supplemental Figure 2). An increased number of mutations 
would decrease the ability of the virus to replicate within the host.
An alternative possibility is that favipiravir initially acted 
synergistically with zanamivir to increase the ability of the 
latter to target the virus; such an effect has been reported in 
vitro [7]. This idea would be consistent with the emergence of 
a fully zanamivir-resistant virus 2 months following the initial 
favipiravir treatment. However, the subsequent clearance of the 
reemergent zanamivir-resistant virus supports a direct role for 
favipiravir; at this stage, zanamivir would have been ineffective.
The initial, favipiravir-associated clearance of influenza B coin-
cided with the infusion of an αβ T cell recept(TCR)-depleted periph-
eral blood hematopoietic stem cell graft. While we cannot exclude the 
possibility that the associated temporary rise in γδcluster of differen-
tiation  (CD) 3+ T- and natural killer (NK)-cells may have contrib-
uted to the drop in the influenza viral load, experience dictates that a 
sustained recovery from influenza requires functioning CD8+ T-cell 
immunity, which was not detectable at this time. The possibility of a 
cryptogenic immune response contributing to viral clearance is also 
raised by a N181D amino acid substitution in the immunogenic por-
tion of the viral haemagglutinin, which was observed in viral samples 
collected after the first use of favipiravir. However, this could equally 
have arisen by chance or in response to replacement immunoglobulin. 
Importantly, the final clearance of the influenza infection occurred in 
the absence of any detectable immune function, further evidencing the 
contribution of favipiravir.
DISCUSSION
Our data show the clinical effectiveness of favipiravir in combi-
nation with zanamivir for treating a severe influenza B infection 
in a severely immunocompromised child. Where in vitro experi-
ments involving repeated passaging have described the mutagenic 
role of this drug, observing an accumulation of C-to-U mutations 
[2, 9], we here show that the same signal may be observed within 
a clinically relevant timescale, as it was detected 6 days after the 
commencement of treatment. Furthermore, where zanamivir and 
nitazoxanide did not detectably alter the viral load, the addition of 
favipiravir was associated, on 2 occasions, with a rapid decline in 
the viral load, as well as with the clearance of the virus following 
its second use. The positive effect of favipiravir is of importance in 
the context of the poor prognosis for individuals receiving trans-
plants while testing positive for respiratory viral infections [12].
The initial treatment with zanamivir failed to clear influenza 
in this chronic infection, although the emergence of partial 
zanamivir resistance is consistent with the drug having some ef-
fect. It is unclear from the clinical data whether favipiravir alone 
would have been effective, or whether favipiravir increased 
the effectiveness of zanamivir. The emergence of a zanamivir-
resistant virus following the treatment of a mixed population is 
consistent with either a very tight bottleneck in the population 
or with increased selection for zanamivir resistance; in vitro ev-
idence suggests that an interaction between the drugs may be 
present [7]. Notwithstanding, this combination was able, on its 
second administration, to clear zanamivir-resistant influenza B, 
supporting the interpretation that favipiravir is intrinsically ef-
fective against the influenza B virus. At higher doses, favipiravir 
has been shown to act as a chain terminator [9]; it remains a 
possibility that favipiravir’s combination with neuraminidase 
inhibitors may boost intracellular levels  of the latter, as in 
‘intracellular levels of the latter’ to enhance its effects.
Our study highlights the value of viral sequencing for the study 
of novel antiviral therapies within human hosts, particularly 
where data from gold-standard randomized clinical trials are not 
available. Given the observation that clearance of the patient’s in-
fluenza virus followed the use of a particular therapy, sequence 
data can provide direct evidence for the effectiveness of a drug 
as the likely cause of the resolution of infection, and help to rule 
out alternative explanations for an observed recovery. In this case, 
no evidence of T-cell or B-cell recovery was observed. Taken to-
gether, our results support the use of favipiravir, combined with a 
neuraminidase inhibitor, as a rational choice for the treatment of 
severe influenza B infection, particularly in profoundly immuno-
suppressed patients.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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